Building the Future of Next-Generation Medicine --- The Complete Omics Milestones
Our journey to build the world’s most comprehensive multi-omics molecular diagnostics platform—and translate deep measurement into clinical practice.
Being trained in Bert Vogelstein’s lab during the birth of cancer genomics in 2007, Qing Wang anticipated translational benefits beyond DNA sequencing and pioneered ultra-deep clinical proteomics, forming the foundation…
As a very 1st project in Qing’s PhD training, he demonstrated that cancer-driving mutant proteins could be directly detected and quantified by mass spectrometry in cancer cells or body fluids—establishing…
Qing Wang completed his PhD in School of Medicine alongside an MHS in Biostatistics in School of Public Health at Johns Hopkins, where the integration of biology, statistics, and multi-omics…
In 2017, Qing Wang pioneered the first clinical proteomics platform for cancer diagnostics, demonstrating that deep measurement of the human plasma proteome could power a new generation of scalable molecular…
In 2019, Qing Wang founded Complete Omics with early angel VC backing to build the world’s leading deep-proteome measurement platform and unlock a new molecular layer for precision medicine. Complete…
In 2019, we introduced a breakthrough targeted proteomics platform enabling direct detection and quantification of cancer neoantigens, demonstrating that carefully optimized assays can reveal previously undetectable therapeutic targets. Direct Detection…
In 2020, we designed the core vision for Complete360: a scalable platform capable of measuring thousands of proteins from plasma, laying the foundation for the clinical measurement layer of the…
In 2021, our work published in Science identified actionable neoantigens from major cancer driver genes such as TP53 and KRAS, defining a new paradigm for precision and personalized cancer immunotherapy.…
In 2022, we discovered a new class of neoantigens derived from human endogenous retroviruses (HERVs) in breast cancer, revealing an untapped therapeutic target space for next-generation precision immunotherapy. Discovery of…
In 2023, Complete Omics secured investment from world-leading venture capital firms, accelerating the scale-up of our clinical proteomics platforms and advancing the measurement infrastructure for next-generation diagnostics and precision medicine.…
In 2024, our laboratory achieved CLIA and CAP certification, enabling the regulated clinical deployment of our proteomics platforms and accelerating the translation of deep proteome measurement into real-world diagnostics. CLIA…